BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 24368307)

  • 1. The dose-dependent macular thickness changes assessed by fd-oct in patients with retinitis pigmentosa treated with ciliary neurotrophic factor.
    Pilli S; Zawadzki RJ; Telander DG
    Retina; 2014 Jul; 34(7):1384-90. PubMed ID: 24368307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal injection of ciliary neurotrophic factor (CNTF) causes peripheral remodeling and does not prevent photoreceptor loss in canine RPGR mutant retina.
    Beltran WA; Wen R; Acland GM; Aguirre GD
    Exp Eye Res; 2007 Apr; 84(4):753-71. PubMed ID: 17320077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa.
    Birch DG; Weleber RG; Duncan JL; Jaffe GJ; Tao W;
    Am J Ophthalmol; 2013 Aug; 156(2):283-292.e1. PubMed ID: 23668681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Follow-up of Patients With Retinitis Pigmentosa Receiving Intraocular Ciliary Neurotrophic Factor Implants.
    Birch DG; Bennett LD; Duncan JL; Weleber RG; Pennesi ME
    Am J Ophthalmol; 2016 Oct; 170():10-14. PubMed ID: 27457255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment.
    Talcott KE; Ratnam K; Sundquist SM; Lucero AS; Lujan BJ; Tao W; Porco TC; Roorda A; Duncan JL
    Invest Ophthalmol Vis Sci; 2011 Apr; 52(5):2219-26. PubMed ID: 21087953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa.
    Tao W; Wen R; Goddard MB; Sherman SD; O'Rourke PJ; Stabila PF; Bell WJ; Dean BJ; Kauper KA; Budz VA; Tsiaras WG; Acland GM; Pearce-Kelling S; Laties AM; Aguirre GD
    Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3292-8. PubMed ID: 12356837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases.
    Kauper K; McGovern C; Sherman S; Heatherton P; Rapoza R; Stabila P; Dean B; Lee A; Borges S; Bouchard B; Tao W
    Invest Ophthalmol Vis Sci; 2012 Nov; 53(12):7484-91. PubMed ID: 23049090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants.
    Sieving PA; Caruso RC; Tao W; Coleman HR; Thompson DJ; Fullmer KR; Bush RA
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3896-901. PubMed ID: 16505355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function.
    Zein WM; Jeffrey BG; Wiley HE; Turriff AE; Tumminia SJ; Tao W; Bush RA; Marangoni D; Wen R; Wei LL; Sieving PA
    Invest Ophthalmol Vis Sci; 2014 Sep; 55(10):6301-8. PubMed ID: 25205868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology.
    Bush RA; Lei B; Tao W; Raz D; Chan CC; Cox TA; Santos-Muffley M; Sieving PA
    Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2420-30. PubMed ID: 15223826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical coherence tomography in retinitis pigmentosa: reproducibility and capacity to detect macular and retinal nerve fiber layer thickness alterations.
    Garcia-Martin E; Pinilla I; Sancho E; Almarcegui C; Dolz I; Rodriguez-Mena D; Fuertes I; Cuenca N
    Retina; 2012 Sep; 32(8):1581-91. PubMed ID: 22922847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa.
    Liang FQ; Aleman TS; Dejneka NS; Dudus L; Fisher KJ; Maguire AM; Jacobson SG; Bennett J
    Mol Ther; 2001 Nov; 4(5):461-72. PubMed ID: 11708883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and spatial distribution of cystoid spaces in retinitis pigmentosa: investigation with spectral domain optical coherence tomography.
    Makiyama Y; Oishi A; Otani A; Ogino K; Nakagawa S; Kurimoto M; Yoshimura N
    Retina; 2014 May; 34(5):981-8. PubMed ID: 24756036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourier-domain optical coherence tomography and microperimetry findings in retinitis pigmentosa.
    Lupo S; Grenga PL; Vingolo EM
    Am J Ophthalmol; 2011 Jan; 151(1):106-11. PubMed ID: 21094934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal nerve fiber layer analysis in RP patients using Fourier-domain OCT.
    Walia S; Fishman GA
    Invest Ophthalmol Vis Sci; 2008 Aug; 49(8):3525-8. PubMed ID: 18421083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.
    Chew EY; Clemons TE; Peto T; Sallo FB; Ingerman A; Tao W; Singerman L; Schwartz SD; Peachey NS; Bird AC;
    Am J Ophthalmol; 2015 Apr; 159(4):659-666.e1. PubMed ID: 25528956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.
    Boyer DS; Faber D; Gupta S; Patel SS; Tabandeh H; Li XY; Liu CC; Lou J; Whitcup SM;
    Retina; 2011 May; 31(5):915-23. PubMed ID: 21487341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optical coherence tomography findings in patients with retinitis pigmentosa and low visual acuity.
    Grigoropoulos VG; Emfietzoglou J; Nikolaidis P; Chatzistefanou K; Vergados J; Theodossiadis GP; Theodossiadis PG
    Ophthalmic Surg Lasers Imaging; 2010; 41(1):35-9. PubMed ID: 20128568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optical coherence tomography-guided retinal prosthesis design: model of degenerated retinal curvature and thickness for patient-specific devices.
    Opie NL; Ayton LN; Apollo NV; Ganesan K; Guymer RH; Luu CD
    Artif Organs; 2014 Jun; 38(6):E82-94. PubMed ID: 24689741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of cone survival in response to CNTF, GDNF, and VEGF165b in a novel ex vivo model of end-stage retinitis pigmentosa.
    Lipinski DM; Singh MS; MacLaren RE
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7340-6. PubMed ID: 21873685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.